Edition:
United States

Compugen Ltd (CGEN.OQ)

CGEN.OQ on NASDAQ Stock Exchange Global Market

3.38USD
20 Jul 2018
Change (% chg)

$-0.12 (-3.57%)
Prev Close
$3.50
Open
$3.50
Day's High
$3.50
Day's Low
$3.35
Volume
11,885
Avg. Vol
44,342
52-wk High
$5.00
52-wk Low
$2.25

Chart for

About

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage... (more)

Overall

Beta: 0.28
Market Cap(Mil.): $189.66
Shares Outstanding(Mil.): 57.20
Dividend: --
Yield (%): --

Financials

  CGEN.OQ Industry Sector
P/E (TTM): -- 217.69 33.34
EPS (TTM): -0.55 -- --
ROI: -61.10 -3.65 13.18
ROE: -65.58 -5.62 15.09

BRIEF-Compugen Ltd - Bayer Plans To Advance Cancer Immunotherapy Program Into First-In-Human Trials In 2018

* COMPUGEN LTD - BAYER PLANS TO ADVANCE CANCER IMMUNOTHERAPY PROGRAM INTO FIRST-IN-HUMAN TRIALS IN 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Apr 17 2018

Deals of the day-Mergers and acquisitions

April 2 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday: ** General Electric Co's healthcare unit said it would sell its information technology business to private equity firm Veritas Capital for $1.05 billion in cash as it sharpens its focus on smart diagnostics and connected devices. ** ReNew Power, backed by Goldman Sachs and Canada Pension Plan Investment Board (CPPIB), said it has acquired Ostro Energy Private Ltd, backed by London-bas

Apr 02 2018

BRIEF-Compugen Announces Exclusive License Agreement With Medimmune

* CO ALSO ELIGIBLE TO RECEIVE UP TO $200 MILLION IN DEVELOPMENT, REGULATORY, COMMERCIAL MILESTONES ON FUTURE PRODUCT SALES Source text (https://bit.ly/2GsywkV) Further company coverage: (Reuters.Brief@thomsonreuters.com)

Apr 02 2018

Compugen, AstraZeneca unit in cancer drug development deal

JERUSALEM, April 2 Israeli drugmaker Compugen Ltd said it had agreed an exclusive licensing deal with a unit of AstraZeneca to develop antibody products to treat cancer, which could be worth more than $200 million.

Apr 02 2018

BRIEF-Compugen Reports Q4 Loss Per Share Of $0.18

* COMPUGEN - AS OF DEC 31, 2017, CASH, CASH RELATED ACCOUNTS, SHORT-TERM AND LONG-TERM BANK DEPOSITS TOTALED $30.4 MILLION, COMPARED WITH $61.5 MILLION LAST YEAR Source text for Eikon: Further company coverage:

Feb 21 2018

Competitors

Earnings vs. Estimates